Article Text

Download PDFPDF
Guideline review
Guideline review: British Society of Gastroenterology/UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis
  1. Alberto Nicoletti1,2,
  2. James B Maurice1,
  3. Douglas Thorburn1
  1. 1 Sheila Sherlock Liver Centre and UCL Institute for Liver and Digestive Health, Royal Free London NHS Foundation Trust, London, UK
  2. 2 Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
  1. Correspondence to Dr James B Maurice, Sheila Sherlock Liver Centre and UCL Institute for Liver and Digestive Health, Royal Free Hampstead NHS Trust, London NW3 5NU, UK; jamesmaurice{at}


New British Society of Gastroenterology/UK-PSC guidelines have recently discussed the current state-of-the-art on primary sclerosing cholangitis and outlined key elements for the management of this disease. The current lack of effective pharmacological treatments to prevent progression of liver fibrosis to cirrhosis limits our ability to modify the natural history of the disease. However, a personalised approach and structured follow-up could allow earlier diagnosis and management of complications and favour access to liver transplantation, which remains the only available treatment. Our commentary overviews the updates and summarises the key recommendations of the recent guidelines for the management of primary sclerosing cholangitis.

  • primary sclerosing cholangitis
  • endoscopic retrograde pancreatography
  • liver cirrhosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @jamesbmaurice

  • Contributors AN reviewed the literature, prepared the initial manuscript and produced tables. JM and DT revised the manuscript critically for important intellectual content.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests JM has received funds from Intercept for internal company training. DT consults for CymaBay Therapeutics and ChemomAb, is a speaker for Dr Falk Pharms UK and Intercept and has participated in advisory boards for CymaBay and Intercept.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles

  • UpFront
    R Mark Beattie